Biogen
3Q Revenues: $3.1 billion (+4%)
3Q Earnings: $1.2 billion (+19%)
YTD Revenues: $9.0 billion (+5%)   
YTD Earnings: $2.8 billion (-7%)
Comments: Multiple sclerosis revenues, including approximately $65 million in royalties on the sales of OCREVUS, were $2.3 billion in the quarter. TECFIDERA sales were $1.1 billion in the quarter, up 3%. Total Interferon sales were $662 million, down 7%. AVONEX sales were also down 7% to $538 million. TYSABRI revenues were $469 million, down 9%. PLEGRIDY sales were down 3% to $124 million. Revenue growth was driven by the launch of SPINRAZA for Spinal Muscular Atrophy, which contributed $271 million in global revenues. Biosimilar product sales were $101 million, up 229%.In 1Q17, Biogen completed the separation of its global hemophilia business, now Bioverativ. Revenues increased 13% excluding all hemophilia revenues from 3Q16. Hemophilia revenues include ELOCTATE and ALPROLIX, as well as royalty and contract manufacturing revenue related to Sobi.